Phil Rackliffe Archives - CDR – Chain Drug Review

Walgreens, Kaléo expand pharmacy program

July 11, 2019 by Chain Drug Review AUVI-q 0.1 mg is the first and only epinephrine auto-injector (EAI) approved by the U.S. Food and Drug Administration (FDA) for infants and toddlers weighing 16.5 to 33 pounds (7.5 to 15 kilograms), Kaleo, Phil Rackliffe, Rina Shah, Walgreens Featured Articles, Leading Headlines, Pharmacy, Retail News

DEERFIELD, Ill. — Walgreens and Kaléo announced Thursday AUVI-q (epinephrine injection, USP) 0.1 mg auto-injector is available at Walgreens locations nationwide. AUVI-q 0.1 mg is the first and only epinephrine auto-injector (EAI) approved by the U.S. Food and Drug Administration (FDA) for infants and toddlers weighing 16.5 to 33 pounds (7.5 to 15 kilograms). Through

Walgreens and kaléo team to address epinephrine auto-injector supply issues

September 6, 2018 by Chain Drug Review anaphylaxis, AUVI-Q AffordAbility program, epinephrine auto-injectors, Kaleo, Phil Rackliffe, Richard Ashworth, Walgreens Leading Headlines, Pharmacy, Retail News

DEERFIELD, Ill. and RICHMOND, Va. — Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q 0.15 mg and 0.3 mg available through Walgreens locations nationwide. This comes in an effort to help thousands of Americans with their epinephrine needs during the back to school